Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$56K Hold
3,826
﹤0.01% 1614
2025
Q4
$48K Hold
3,826
﹤0.01% 1651
2025
Q3
$59K Hold
3,826
﹤0.01% 1589
2025
Q2
$60K Sell
3,826
-2,028
-35% -$30.7K ﹤0.01% 1515
2025
Q1
$112K Buy
5,854
+127
+2% +$2.78K ﹤0.01% 1419
2024
Q4
$137K Buy
5,727
+1,672
+41% +$46.7K ﹤0.01% 1351
2024
Q3
$114K Buy
4,055
+890
+28% +$25.1K ﹤0.01% 1210
2024
Q2
$83K Hold
3,165
﹤0.01% 1287
2024
Q1
$69K Hold
3,165
﹤0.01% 1345
2023
Q4
$74K Hold
3,165
﹤0.01% 1260
2023
Q3
$62K Sell
3,165
-5,501
-63% -$108K ﹤0.01% 1292
2023
Q2
$196K Sell
8,666
-1,085
-11% -$21.9K ﹤0.01% 942
2023
Q1
$192K Buy
+9,751
New +$187K ﹤0.01% 990

Other funds holding RXO

KBC Group's RXO Position: Q1 2026 in Review

KBC Group held its RXO (RXO) position steady in Q1 2026 at 3,826 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #1614.

KBC Group first reported a position in RXO in Q1 2023 and has held it in 13 quarters since. The position peaked at $196K in Q2 2023. 275 funds tracked by Wall St. Rank hold RXO as of Q1 2026.

  • KBC Group held 3,826 shares of RXO worth $56K as of Q1 2026.
  • KBC Group left its RXO share count unchanged in Q1 2026.
  • RXO made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1614 holding.
  • KBC Group first reported a position in RXO in Q1 2023 and has held it in 13 quarters since.
  • KBC Group's RXO position peaked at $196K in Q2 2023.
  • 275 funds tracked by Wall St. Rank held RXO as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.